The table below is a summary of the segment net loss, including significant segment expenses (in millions):


	Three Months Ended March 31,
		2026		2025
Total revenues		17		28
Adjusted for expense (income):
Late-stage development programs (1)		60		55
Early-stage development and preclinical programs (2)		18		42
Compensation and personnel costs		70		66
Depreciation and amortization		2		3

Interest income, net		(6)		(10)

Other segment items (3)		20		22
Partnership reimbursements		(19)		(38)
Segment net loss and Consolidated net loss		$	(128)	$	(112)

(1) R&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.

(2) R&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.